Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2

Christina M. Annunziata, Amanda J. Walker, Lori Minasian, Minshu Yu, Herbert Kotz, Bradford J. Wood, Katherine Calvo, Peter Choyke, Daniel Kimm, Seth M. Steinberg, Elise C. Kohn

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2'. Together they form a unique fingerprint.

Medicine & Life Sciences